Acumen Pharmaceuticals, Inc. to Post Q1 2023 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:ABOS)

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) – Equities researchers at HC Wainwright issued their Q1 2023 earnings estimates for Acumen Pharmaceuticals in a report issued on Tuesday, March 28th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and […]

Related Keywords

,Acumen Pharmaceuticals Company Profile ,Credit Suisse Group ,Acumen Pharmaceuticals ,News Ratings For Acumen Pharmaceuticals Daily ,Acumen Pharmaceuticals Stock Down ,Acumen Pharmaceuticals Inc ,Vanguard Group Inc ,Nasdaq ,Blackrock Inc ,Hedge Funds Weigh In On Acumen Pharmaceuticals ,Millennium Management ,Get Rating ,Acumen Pharmaceutical ,Suisse Group ,Pharmaceuticals Stock Down ,Laurion Capital Management ,Capital Management ,Acumen Pharmaceuticals Daily ,Nasdaq Abos ,Cabos ,Medical ,Earnings Estimates ,Hc Wainwright ,